Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: http://www.sciepub.com/journal/jcrt Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Go
Journal of Cancer Research and Treatment. 2018, 6(3), 60-69
DOI: 10.12691/jcrt-6-3-1
Open AccessArticle

Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells

Callinice D. Capo-chichi1, 2, , Freddy Gnangnon3, Charles Mekpossi1, Sara Houngue1, Xiang-Xi Xu2 and Jean-Leon Olory-Togbé3

1Institute of Biomedical Sciences and Applications (ISBA), Division of Molecular Biomarkers in Cancer and Nutrition (BMCN), Department of Biochemistry and Cell biology, Faculty of Sciences and Technology (FAST), University of Abomey-Calavi (UAC)

2Sylvester Comprehensive Cancer Center, Miller Medical School, University of Miami

3Visceral Surgery, National University Hospital (CNHU-HKM), School of Medicine, University of Abomey-Calavi (UAC)

Pub. Date: August 01, 2018

Cite this paper:
Callinice D. Capo-chichi, Freddy Gnangnon, Charles Mekpossi, Sara Houngue, Xiang-Xi Xu and Jean-Leon Olory-Togbé. Presence of Lamin A is Required for GATA3 and ERα Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells. Journal of Cancer Research and Treatment. 2018; 6(3):60-69. doi: 10.12691/jcrt-6-3-1

Abstract

Background: Breast cancer treatment is challenging due to the inconsistence in tumour biomarker expression including progesterone receptor (PR), estrogen receptor-α (ERα) and GATA3 transcription factor. GATA3 has role in epithelial cell differentiation along with nuclear envelope protein lamin A. The breast cancer cell line MCF7 expresses ERα, abnormal GATA3 isoforms, low PR but lacks lamin A. MCF7 cells are resistant to tamoxifen targeting ERα and more anticancer drugs are being studied to kill them. One of the mechanisms surrounding breast cancer initiation is histone deacetylation. Our objective is to investigate the effect of histone deacetylase inhibitor (HDACI) on PR, ERα and GATA3 expression along with the induction of apoptosis in MCF7 cells forced expressing lamin A. Subsequently, they are also explored as biomarkers for breast cancer prognostic and indicators for targeted breast cancer therapy. Methods: The HDACI used here is Suberoyl-Bis-Hydroxamic Acid (SBHA). Western blot was used to analyze the expression of PR, ERα, and GATA3 in MCF7 control transfected with histone H2B-GFP (MCF7-H2B-GFP) and in MCF7 transfected with lamin A-RFP (MCF7-LA-RFP). The analyses were carried out before and after treatment with DMSO (mock) or SBHA (1 or 2 µM) for 12h. The in vivo expression of the PR, ERα and GATA3 were also explored in 36 archived cell lysates derived from breast cancer micro-biopsies. Results: MCF7-H2B-GFP treated with SBHA increased PR, ERα while MCF7-LA-RFP treated with SBHA reduced ERα and GATA3 but not PR. Biomarkers analysis in ductal carcinoma micro-biopsies derived samples showed that 30% had lost lamin A while 64% expressed PR, ERα and GATA3. Conclusion: In presence of lamin A, SBHA downregulated cancer initiators GATA3 and ERα while inducing cell death. These biomarkers could be useful molecular tools prior to initiating targeted breast cancer therapy.

Keywords:
Suberoyl-Bis-Hydroxamic Acid GATA3 ERα targeted breast cancer therapy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 8

References:

[1]  Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ. Progesterone receptor activation down regulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth, Breast Cancer Res.; 16:491, 2014.
 
[2]  Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale AL, Perou CM. Mutation of GATA3 in human breast tumors. Oncogene; 23:7669-7678, 2004.
 
[3]  Mair B, Konopka T, Kerzendorfer C, Sleiman K, Salic S, Serra V, Muellner MK, Theodorou V, Nijman SM. Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genet; 12(9):e1006279, 2016.
 
[4]  Capo-chichi CD, Cai KQ, Smedberg J, Ganjei-Azar P, Godwin AK, Xu XX. Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer; 30: 415-425, 2011.
 
[5]  Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res.; 65:11259-11264, 2005.
 
[6]  Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res.; 67: 6477-6483, 2007.
 
[7]  Sikora MJ, Strumba V, Lippman ME, Johnson MD, Rae JM. Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res Treat; 134: 1027-1039, 2012.
 
[8]  Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA, Arenas-Aranda D. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep; 32:3-159, 2014.
 
[9]  Zhuang Z, Fei F, Chen Y, Jin W. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin; 29 (12): 1459–1466, 2008.
 
[10]  Yang X, Zhang N, Shi Z, Yang Z, Hu X. Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells. Mol Med Rep., 11: 2908-2912, 2015.
 
[11]  Capo-Chichi CD, Yeasky TM, Smith ER, Xu XX. Nuclear envelope structural defect underlies the main cause of aneuploidy in ovarian carcinogenesis. BMC Cell Biol., 17:37, 2016
 
[12]  Capo-chichi CD, Aguida B, Chabi NW, Cai QK, Offrin G, Agossou VK, Sanni A, Xu XX. Lamin A/C deficiency is an independent risk factor for cervical cancer. Cell Oncol (Dordr); 39: 59-68, 2016.
 
[13]  Liu F, Wang L, Perna F, Nimer SD. Beyond transcription factors: how oncogenic signaling reshapes the epigenetic landscape. Nat Rev Cancer; 16: 359-372, 2016.
 
[14]  Frietze S, Wang R, Yao L, Tak YG, Ye Z, Gaddis M, Witt H, Farnham PJ, Jin VX. Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3. Genome Biol.;13:R52, 2012
 
[15]  Adomas AB, Grimm SA, Malone C, Takaku M, Sims JK, Wade PA1. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. BMC Cancer, 14:278, 2014.